Neighborhood Health Plan RI IV Tocilizumab Coverage

Coverage Criteria for Intravenous Tocilizumab

inv-01: General initial and continuation requirements

Covered when ALL of the following are met:

General Initial Requirements: Patient evaluated and screened for latent tuberculosis infection prior to initiating therapy; no active infection (including clinically important localized infections); not administered concurrently with live vaccines; not on concurrent biologic therapy or specified targeted synthetic therapies (examples include other IL inhibitors, TNF inhibitors, integrin receptor antagonists, T‑cell costimulation modulators, apremilast, abrocitinib, tofacitinib, upadacitinib, ruxolitinib, etrasimod, etc.); for Actemra (tocilizumab) or Tofidence (tocilizumab‑bavi) requests, inadequate response or intolerance to at least a 3‑month trial of Tyenne (tocilizumab‑aazg) is required; Medicare members who received this medication within the past 365 days may be exempt from step therapy requirements.

Examples of excluded concurrent therapies and step therapy exceptions provided in policy.

Continuation Requirements: Patient continues to meet all initial criteria and has no unacceptable toxicity (examples include serious infection, severe neutropenia, severe thrombocytopenia, severe hepatotoxicity); AND there is documented disease response per indication‑specific response measures.

Unacceptable toxicity examples listed in policy.

inv-02: Rheumatoid Arthritis (initial)

Covered when ALL of the following are met:

Age and disease: Patient is ≥18 years of age with documented moderate to severe active rheumatoid arthritis; physician has assessed baseline disease severity using an objective measure/tool.

Prior therapy: Patient has had at least a 3‑month trial and failure of one conventional synthetic DMARD (e.g., methotrexate, azathioprine, hydroxychloroquine, sulfasalazine, leflunomide) AND has had inadequate response, intolerance, or contraindication to at least a 3‑month trial of adalimumab at maximum tolerated doses; OR patient is already established on biologic or targeted synthetic therapy for RA.3 months

Tocilizumab may be used as monotherapy or in combination with csDMARDs.

inv-03: Systemic and Polyarticular Juvenile Idiopathic Arthritis (initial)

Covered when ALL of the following are met:

Age and diagnosis: Patient is at least 2 years of age with active systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (PJIA); physician has assessed baseline disease severity using an objective measure/tool.age ≥2

Prior therapy: Patient has had at least a 1‑month trial and failure (unless contraindicated or intolerant) of NSAIDs OR csDMARDs (e.g., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) AND has had inadequate response, intolerance, or contraindication to at least a 3‑month trial of adalimumab at maximum tolerated doses; OR patient is already established on biologic or targeted synthetic therapy for sJIA/PJIA.1 month for NSAID trial; 3 months for adalimumab

May be used alone or in combination with methotrexate.

inv-04: Giant Cell Arteritis (initial)

Covered when ALL of the following are met:

Diagnosis and activity: Large‑vessel arteritis confirmed by temporal artery biopsy or vessel imaging (color Doppler ultrasound, MRI, PET‑CT, or CT angiography); AND active disease with elevated C‑reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR).

Prior therapy: Inadequate response, contraindication, or intolerance to glucocorticoid therapy alone; tocilizumab is used in combination with a tapering course of glucocorticoids (tocilizumab may be used alone after glucocorticoid discontinuation).

inv-05: Neuromyelitis Optica Spectrum Disorder (NMOSD) (initial and continuation)

Covered when ALL of the following are met:

Diagnostic confirmation: Confirmed NMOSD diagnosis with AQP4‑IgG seropositivity and at least one core clinical characteristic; alternative diagnoses (e.g., MOGAD, multiple sclerosis, sarcoidosis, cancer, chronic infection) excluded. If AQP4‑IgG is seronegative or unknown, patient must have at least two core clinical characteristics occurring as the result of one or more clinical attacks and meet MRI requirements.

Clinical and MRI criteria: Core clinical characteristics consistent with NMOSD (e.g., optic neuritis, acute myelitis with LETM, area postrema syndrome, brainstem/diencephalic/cerebral syndromes) with fulfillment of typical MRI findings appropriate to the clinical presentation; therapy may be used as monotherapy or in combination with other immunosuppressive agents (e.g., azathioprine, methotrexate, mycophenolate).

LETM defined as intramedullary lesion spanning ≥3 contiguous vertebral segments.

Continuation/response: Documented disease response demonstrated by stabilization or improvement (for example: decreased acute relapses, reduced hospitalizations, reduction/discontinuation of plasma exchange treatments, and/or reduction/discontinuation of corticosteroids without relapse).

inv-06: Management of Immune Checkpoint Inhibitor (ICI) Related Toxicities

Covered when ALL of the following are met:

Context and indication: Patient is receiving immune checkpoint inhibitor (ICI) therapy and tocilizumab is being used as additional DMARD for ICI‑related giant cell arteritis or moderate/severe inflammatory arthritis; symptoms have not improved after holding immunotherapy and patient has not responded to oral corticosteroids or is unable to taper corticosteroids.

Other ICI‑toxicity uses: Used as corticosteroid‑sparing immunosuppression for polymyalgia rheumatica unable to taper prednisone, or for specified hepatic or alkaline phosphatase elevations that do not improve within policy‑specified timeframes after corticosteroids (e.g., G2 ALT/AST not improved after 3–7 days; G3–G4 ALT/AST not improved after 1–2 days; similar grade‑based windows for alkaline phosphatase).timeframes per liver/ALP grade

Specific grade‑based windows and examples provided in policy.

inv-07: Rheumatoid arthritis (RA) — response criteria

Covered when disease response criteria are used to assess effectiveness for rheumatoid arthritis

Rheumatoid arthritis response criteria: Improvement in signs and symptoms from baseline demonstrated by reductions in tender and swollen joint counts, decreased C‑reactive protein, improvement in patient global assessment, and/or improvement on disease activity scoring tools (e.g., DAS28 improvement of ≥1.2 points or improvement per ACR response criteria).DAS28 improvement >=1.2 or ACR improvement

These measures are used to document response for continuation of therapy.

inv-08: Polyarticular and systemic juvenile idiopathic arthritis — response criteria

Covered when disease response criteria are used to assess effectiveness for juvenile idiopathic arthritis

Juvenile idiopathic arthritis response criteria: Improvement in signs and symptoms from baseline demonstrated by reductions in tender and swollen joint counts, decreased C‑reactive protein, improvement in patient global assessment, and/or improvement on disease activity scoring tools (e.g., JADAS or ACR Pedi criteria such as ACR Pedi‑30: ≥30% improvement in 3 of 6 variables).ACR Pedi 30 or equivalent

These pediatric response measures are used to document response for continuation of therapy.

inv-09: Indication-specific dosing and duration

Coverage tied to indication-specific dosing and duration

Immune checkpoint inhibitor–related toxicities: Single IV dose of 4 mg/kg (one course); initial approval duration = 1 dose; continuation not permitted.1 dose

Policy specifies single‑dose approval for ICI‑related toxicities.

Adult rheumatoid arthritis dosing: Initiate at 4 mg/kg IV every 4 weeks with increase to 8 mg/kg every 4 weeks based on clinical response; maximum billable dose unit up to 800 units every 28 days (doses exceeding specified maximums not recommended).up to 8 mg/kg; billable unit up to 800 units per 28 days

Dosing guidance and maximum billable unit included.

Polyarticular juvenile idiopathic arthritis dosing: For weight ≥30 kg: 8 mg/kg IV every 4 weeks; other pediatric weight‑based dosing described; billable unit up to 800 units every 28 days.

inv-10: Investigational / not covered uses

Investigational use

Investigational uses or doses: Therapies used at doses or for conditions other than those recognized as medically accepted indications (per standard compendia or peer‑reviewed literature) are considered investigational and are not covered by Neighborhood Health Plan of Rhode Island.Not applicable

Policy references standard compendia (AHFS‑DI, Micromedex DrugDex, Clinical Pharmacology, Lexi‑Drugs) and peer‑reviewed literature.

Concurrent administration of tocilizumab with another biologic therapy or specified targeted synthetic therapies is not permitted. Examples include other interleukin inhibitors, tumor necrosis factor inhibitors, integrin receptor antagonists, T‑cell costimulation modulators, and targeted synthetics such as apremilast, abrocitinib, tofacitinib, upadacitinib, ruxolitinib, and etrasimod. Requests that document concurrent use with these agents do not meet the initial criteria for coverage and may be denied.

Uses or dosing that are outside the recognized, medically accepted indications or doses listed in standard compendia are considered investigational and are not covered. Neighborhood defines investigational uses as therapies given at a dose or for a condition not supported by reliable reference sources (e.g., AHFS, DrugDex, Clinical Pharmacology, Lexi‑Drugs) or peer‑reviewed literature; such requests will be denied.

Coverage of tocilizumab is contingent on meeting the policy criteria and is reviewed prospectively through prior authorization. Use outside the stated guidelines or submission of requests that do not meet the documented criteria (including investigational indications or non‑recognized dosing) may result in non‑payment.

Provider Requirements, Authorization, and Documentation

Prior Authorization

Prior authorization required

Coverage of tocilizumab will be reviewed prospectively via the authorization process; prior authorization is required for medical benefit coverage when used for non-oncology indications.

Prior Authorization

Prior authorization required for listed HCPCS/CPT codes

Requests submitted using the listed HCPCS/CPT codes for tocilizumab (J3262 and biosimilar codes Q5133/Q5135) require review and must meet all clinical criteria in the procedure section; submission of a code does not guarantee coverage.

J3262
Q5133
Q5135

Step Therapy

Billing and Coding

Applicable HCPCS/CPT codesHCPCS

J3262	Injection, tocilizumab, 1 mg (Actemra)
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg

Background

Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist approved for multiple inflammatory, non‑oncology conditions including adult rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and neuromyelitis optica spectrum disorder among others. Intravenous formulations are administered in indication‑specific, weight‑based regimens (for example, adult RA often starts at 4 mg/kg IV every 4 weeks with an increase to 8 mg/kg based on clinical response; giant cell arteritis dosing is 6 mg/kg IV every 4 weeks with doses >600 mg not recommended). Efficacy has been demonstrated in randomized trials for labeled indications, and dosing limits and maximum billable units are specified in the administration section.

Definitions and Clinical Concepts

LETM (NMOSD MRI) definition

DefinitionLongitudinally extensive transverse myelitis (LETM) — an intramedullary spinal cord lesion spanning ≥3 contiguous vertebral segments on MRI.

Imaging modalityTypically identified on T2-weighted (or T2/T1 with gadolinium as indicated) spinal MRI sequences showing contiguous segment involvement.

Clinical contextLETM is described as a typical MRI finding for NMOSD-related myelitis and supports a core clinical characteristic for NMOSD diagnosis.

Differential noteLETM helps distinguish NMOSD from other causes (e.g., multiple sclerosis) where lesions are usually shorter and not spanning ≥3 vertebral segments.

Disease response — improvement metrics

DefinitionDisease response — improvement in signs and symptoms from baseline such as reductions in tender and swollen joint counts, decreased C-reactive protein, and improved patient global assessment.

OpenPayer

Tocilizumab: Actemra, Tofidence, Tyenne NON-ONCOLOGY POLICY (Intravenous)

Coverage Criteria for Intravenous Tocilizumab

Provider Requirements, Authorization, and Documentation

Billing and Coding

Background

Definitions and Clinical Concepts